Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison
Aim: Despite the availability of novel treatment options for patients with triple-class exposed/refractory multiplemyeloma , there is a lack of consensus on the optimal regimen. A previous unanchored matchingadjusted indirect comparison (MAIC) of the MagnetisMM-3 (NCT04649359) and LocoMMotion (NCT...
Saved in:
| Main Authors: | Isha Mol, Yannan Hu, Thomas W LeBlanc, Joseph C Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Isabel Perez Cruz, Patrick Hlavacek |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2025-04-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician’s Choice of Treatment in Spain
by: Cristina Encinas, et al.
Published: (2025-04-01) -
Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma
by: Shah B, et al.
Published: (2025-04-01) -
Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma
by: Carmen Tsang, et al.
Published: (2025-07-01) -
An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma
by: Costa LJ, et al.
Published: (2025-06-01) -
Unexpected hope for a multiple myeloma patient
by: Minodora Cezarina Onisâi, et al.
Published: (2020-10-01)